The global genome editing market was valued at $4,811.04 Million in 2022 and is projected to reach $36,060.95 Million by 2032 registering a CAGR of 22.30% from 2023 to 2032.
Genome editing is also referred to as gene editing, a group of technologies that enables researchers to change the DNA of an organism. These technologies allow addition, removal or alteration of genetic material at specific locations in the genome. In addition, various approaches have been developed for genome editing. A recent one is called CRISPR-Cas9, short for regularly clustered regularly interspaced short palindrome repeats and CRISPR-associated protein9. Furthermore, a lot of excitement has been generated in the scientific community through the CRISPR-Cas9 system, which is faster, cheaper, and more efficient than other existing genome editing methods.
Moreover, the prevention and treatment of human diseases is of great importance to genome editing. Most research is currently being done on genome editing to better understand diseases using cell and animal models. Scientists are still investigating whether this approach is safe and effective for human use. It is being explored in research on a wide range of diseases, such as single-gene diseases like hemophilia, cystic fibrosis, and sickle cell disease. It also has the potential to treat and prevent complex diseases such as heart disease, cancer, human immunodeficiency virus (HIV) infection, and mental illness.
Request a Sample@ https://www.qyresearchmedical.com/sample/119547
The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. Moreover, there has also been a moderate effect on various healthcare services, including the including genome editing market. When COVID-19 was first identified, many researchers redirected their focus to the study of this novel virus and the disease it causes. Individuals working with CRISPR were no exception, and the gene editing tool was soon taken to the frontlines in the worldwide war against COVID-19. Furthermore, with the technology based upon a naturally occurring bacterial gene editing system that plays a key role the prokaryotic defense against viral infection, the CRISPR—Cas system is designed to fight viruses. The challenge researchers are facing now is how best to utilize its natural ability and optimize it for human benefit. At this time, scientists have certainly risen to the occasion and CRISPR technology has been successfully used to develop rapid diagnostic tests for COVID-19 – gaining its first US FDA (MD, USA) approval in the process. Furthermore, development of CRISPR -based novel diagnostic tools to ease the adverse impact of the COVID-19 pandemic is driving the market. For instance, in March 2022, a team of researchers from the Nanyang Technological University developed a diagnostic test – VaNGuard (Variant Nucleotide Guard) based on CRISPR technology. This test can detect mutated SARS-CoV-2 strains, thereby increasing the adoption of CRISPR genome editing technology in the diagnostics field. Hence, the overall impact of COVID-19 on genome editing market is positive, which will further drive the market growth.
Genome Editing Market Segmentation
The global genome editing market is segmented on the basis of application, technology, end user and region. On the basis of application, the market is further classified into cell line engineering, genetic engineering, drug discovery, gene modified cell therapy & diagnostics and other applications. By technology, it is divided into CRISPR, TALEN, ZFN and other technologies. Based on end user, it is subdivided in to academics & government institutes, biotechnology & pharma companies, contract research organizations. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Segment Review
By technology, the CRISPR segment accounted for the largest share of the genome editing market in 2022. The large share of this segment can be attributed to the ease of use associated with CRISPR, which gives it a significant advantage over ZFN and TALEN.
Snapshot of North America Genome Editing market
North America is projected to account for a major share of the global genome editing market during the forecast period. The market in the region is anticipated to grow in the future, owing to development of gene therapy in the U.S., rise in use of genetically modified crops, surge in prevalence of infectious diseases and cancer, and the availability of research grants and funding are propelling market growth in North America.
The key market players profiled in the report include Agilent Technologies, CRISPR Therapeutics, Danaher, Eurofins Scientific, Editas Medicine, GenScript, Horizon Discovery Limited, Lonza, Merck and Thermo Fisher Scientific.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the global genome editing market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2022 to 2032 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products the market used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Segments Covered in the Report:
By Application
- Cell line engineering
- Genetic Engineering
- Drug Discovery
- Gene-modified cell therapy and Diagnostics
- Other Applications
By Technology
- CRISPR
- TALEN
- ZFN
- Other technologies
By End User
- Academics & Government Institutes
- Biotechnology & Pharma Companies
- Contract Research Organizations
By Region
- North America
-
- U.S.
- Canada
- Mexico
- Europe
-
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
-
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
-
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Buy quantitative research Report at discounted price – USD 1599 https://www.qyresearchmedical.com/report/checkout/119547/
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
About Us
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/